Navigation Links
Lo studio EXAMINE della Takeda sulla sicurezza cardiovascolare di alogliptin in aggiunta alla terapia standard ha soddisfatto l'endpoint primario di non inferiorità rispetto al placebo dimostrando che non si verifica nessun incremento del rischio ca
Date:9/17/2013

AMSTERDAM, Paesi Bassi e OSAKA, Giappone, 17 settembre 2013 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (Takeda) ha annunciato oggi i risultati di EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome) studio di outcome sulla sicurezza cardiovascolare, mostrando come l'endpoint primario di non-inferiorità di alogliptin rispetto al placebo in aggiunta alla normale terapia standard sia stato soddisfatto con l'assenza di incremento del rischio cardiovascolare in una popolazione di pazienti con diabete di tipo 2 a elevato rischio di eventi cardiovascolari. Questi dati, pubblicati nel New England Journal of Medicine (NEJM) e presentati anche al congresso ESC 2013, dimostrano che alogliptin non aumenta il rischio cardiovascolare nei pazienti affetti da diabete di tipo 2 che presentano un elevato rischio di eventi avversi cardiaci maggiori (MACE) a causa di una recente sindrome coronarica acuta (ACS). L'obiettivo principale dello studio era valutare la non inferiorità di alogliptin rispetto al placebo, nel rischio cardiovascolare basato su un endpoint primario composito di morte per cause cardiovascolari, infarto non fatale del miocardio e ictus non fatale. L'endpoint primario ha fatto registrare tassi simili nel gruppo trattato con alogliptin e in quello trattato con placebo (rispettivamente nell'11,3% dei pazienti rispetto all'11,8% dei pazienti nel corso di un periodo di follow-up mediano di 18 mesi; hazard ratio, 0,96; limite superiore dell' intervallo di confidenza unilaterale ripetuto [CI], 1,16). Alogliptin è un inibitore del dipeptidil peptidasi-4 (DPP-4i) per il trattamento del diabete di tipo 2 negli adulti, utilizzato per migliorare il controllo glicemico in aggiunta a dieta ed esercizio fisico.

"Esiste la necessità di terapie più sicure per la riduzion
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Anthony Creed Joins DDSTUDIO As GM, Experience Design
2. Daiichi Sankyo ha completato larruolamento dei pazienti per lo studio Hokusai-VTE su Edoxaban, il più ampio trial clinico di fase 3 per il trattamento delle tromboembolie venose ricorrenti
3. Lo studio pubblicato su European Radiology esalta ulteriormente lutilizzo della tomosintesi al seno di Hologic nellambito dello screening del cancro con utilizzo della doppia lettura
4. I benefici della tecnologia Hologic per lutilizzo della Tomosintesi in vengono corroborati dalla pubblicazione di uno studio italiano
5. Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2
6. River City Laser Tattoo Removal Studio Offers Grand Opening Discounts on Treatments Using the Astanza Revolution Laser
7. New post-hoc analyses examined Neupro® effects on pain, depressed mood, apathy and fatigue in patients with Parkinsons disease
8. New 2012 Cold Chain Report Examines the Extent of Temperature Excursions During the Handling of Temperature-Sensitive Pharmaceutical Shipments
9. Study Examines Smart Pharma Strategies for Effective Messaging around New Products and the Medical Conditions they Treat
10. TeamHealth White Paper Examines Telemedicine Risks, Risk Management Strategies
11. The Food Journal Examines Dietary Supplements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 2014 Research and Markets ( ... "Investment Analysis of the US Medical Device ... http://photos.prnewswire.com/prnh/20130307/600769 ... device sector identifies the key trends and rationale ... and mergers and acquisitions. The study ...
(Date:12/22/2014)... and STOCKHOLM , Dec. 22, 2014 ... partner Auxilium Pharmaceuticals, Inc. today announced that the Committee ... European Medicines Agency (EMA) has adopted a positive opinion ... the treatment of adult men with Peyronie,s disease with ... 30 degrees at the start of therapy. ...
(Date:12/22/2014)... , Dec, 22, 2014  Eiger BioPharmaceuticals Incorporated ... study of lonafarnib in patients with chronic hepatitis ... at the National Institutes of Health (NIH) Clinical ...  The double-blinded, randomized, placebo-controlled, dose ascending study evaluated ... and 200 mg twice daily for 28 days.  ...
Breaking Medicine Technology:Investment Analysis of the US Medical Device Sector 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3
... Nektar Therapeutics (NASDAQ: NKTR ) today ... research scientists at the company,s existing San Francisco ... the UCSF research and medical campus in Mission ... Huntsville, Alabama research site will be relocating to ...
... NEW YORK, March 20, 2012 Reportlinker.com ... is available in its catalogue: ... Global Market Analysis, Size, Share & Forecast ... http://www.reportlinker.com/p0797075/Magnetic-Resonance-Imaging-MRI-Market-Global-Market-Analysis-Size-Share--Forecast-2012---2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging Description ...
Cached Medicine Technology:Nektar Consolidates Research at Its State-of-the-Art R&D Center Located in San Francisco at Mission Bay 2Nektar Consolidates Research at Its State-of-the-Art R&D Center Located in San Francisco at Mission Bay 3Nektar Consolidates Research at Its State-of-the-Art R&D Center Located in San Francisco at Mission Bay 4Nektar Consolidates Research at Its State-of-the-Art R&D Center Located in San Francisco at Mission Bay 5Magnetic Resonance Imaging (MRI) Market: Global Market Analysis, Size, Share & Forecast (2012 - 2017) 2Magnetic Resonance Imaging (MRI) Market: Global Market Analysis, Size, Share & Forecast (2012 - 2017) 3Magnetic Resonance Imaging (MRI) Market: Global Market Analysis, Size, Share & Forecast (2012 - 2017) 4
(Date:12/25/2014)... December 25, 2014 When head lice hits ... in a frenzy to get rid of it while keeping ... in Coral Gables now have the solution right in their ... clinic location, Lice Troopers provides full spectrum head lice screening ... Gable area, including Sunset, Key Biscayne, Brickell, Coconut Grove, Kendall, ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. 24, 2014 ... can receive effective, less expensive care from a clinic that ... team of dedicated health care professionals, a new study shows. ... need either hospitalization or a trip to the emergency room ... at the University of Texas in Houston versus usual care, ...
(Date:12/25/2014)... -- Overeating is common during the holidays, but there are ... says. "Don,t arrive at a party hungry. It may ... be attending a party, but deprivation leads to hunger, and ... Westchester Hospital in Mount Kisco, N.Y., said in a hospital ... day and even to have a snack before attending a ...
(Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... could be closing in on a "fountain of youth" drug ... health of older adults, a new study suggests. Seniors ... a drug that targets a genetic signaling pathway linked to ... report. The experimental medication, a version of ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Thousands of ... move forward in a number of multidistrict litigations currently ... Virginia, Bernstein Liebhard LLP reports. According to an Order ... to convene a Joint Status Conference in all of ... Parties have been directed to submit a proposed agenda ...
Breaking Medicine News(10 mins):Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4
... , ... has established a strong link between elevated commitment among employees and positive business outcomes. ... Charlotte, NC ... host a webinar titled “Building Workforce Commitment.” The free hour-long webinar will be ...
... ... clients, connecting them with the best-in-class partners around the world, delivering the ultimate experience ... ... a different connotation today than the decades old call center depiction. Clients today ...
... Hospitals ... use” of certified Electronic Medical Record (EMR) systems under the American Recovery and Reinvestment ... ... (ARRA) hospitals and physicians can receive $19 billion in subsidies over five years for ...
... ... SEO firm in 2001 under the name of Anna Tulchinsky Web Consultancy, Joomla Bliss was ... quality or professionalism. The firm is offering several website design + SEO packages tailored specifically ... , ...
... , ... on Interferential mode, is reducing the severity, duration and frequency of pain for many patients ... weeks between treatments. , ... March 9, 2010 -- The Infrex Plus Unit from MedFaxx, when used on Interferential Mode, ...
... ... ... , ... ...
Cached Medicine News:Health News:Morehead Webinar to Discuss Building Workforce Commitment 2Health News:Announcing the Evolution of Provider Placement Methodology – EPIC Connections 2Health News:Three Security Firms Create Consortium To Automate Meaningful Use Requirements And Qualify Clients For $Billions In Stimulus Funds 2Health News:Three Security Firms Create Consortium To Automate Meaningful Use Requirements And Qualify Clients For $Billions In Stimulus Funds 3Health News:Recession Buster for Small Businesses: Website Design and Search Engine Optimization on a Shoestring 2Health News:Recession Buster for Small Businesses: Website Design and Search Engine Optimization on a Shoestring 3Health News:The Infrex Plus is Revolutionizing Pain Control by Stopping Pain & Eliminating Drugs for Chronic Pain Patients Who Suffered For Years 2Health News:The Infrex Plus is Revolutionizing Pain Control by Stopping Pain & Eliminating Drugs for Chronic Pain Patients Who Suffered For Years 3Health News:The Infrex Plus is Revolutionizing Pain Control by Stopping Pain & Eliminating Drugs for Chronic Pain Patients Who Suffered For Years 4Health News:New Report Says Hispanics Are One and One-Half Times More Likely to Have Alzheimer's Disease and Dementia Than Whites 2Health News:New Report Says Hispanics Are One and One-Half Times More Likely to Have Alzheimer's Disease and Dementia Than Whites 3Health News:New Report Says Hispanics Are One and One-Half Times More Likely to Have Alzheimer's Disease and Dementia Than Whites 4Health News:New Report Says Hispanics Are One and One-Half Times More Likely to Have Alzheimer's Disease and Dementia Than Whites 5Health News:New Report Says Hispanics Are One and One-Half Times More Likely to Have Alzheimer's Disease and Dementia Than Whites 6Health News:New Report Says Hispanics Are One and One-Half Times More Likely to Have Alzheimer's Disease and Dementia Than Whites 7Health News:New Report Says Hispanics Are One and One-Half Times More Likely to Have Alzheimer's Disease and Dementia Than Whites 8Health News:New Report Says Hispanics Are One and One-Half Times More Likely to Have Alzheimer's Disease and Dementia Than Whites 9
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: